radioimmunotherapy

Summary

Summary: Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).

Top Publications

  1. pmc Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer
    Scott T Tagawa
    Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA
    Cancer 116:1075-83. 2010
  2. doi Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma
    Pierre Yves Salaun
    Nuclear Oncology Department, Cancer Research Center, INSERM U892, Universite de Nantes, Nantes, France
    Cancer 116:1053-8. 2010
  3. ncbi 131I-tositumomab therapy as initial treatment for follicular lymphoma
    Mark S Kaminski
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109 0936, USA
    N Engl J Med 352:441-9. 2005
  4. pmc Cancer radioimmunotherapy
    Robert M Sharkey
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Immunotherapy 3:349-70. 2011
  5. ncbi Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft
    Françoise Kraeber-Bodéré
    INSERM UMR 892 Cancer Research Center, Universite de Nantes, Nantes, France
    J Nucl Med 51:624-31. 2010
  6. doi Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice
    Birgit Pfost
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 50:1700-8. 2009
  7. ncbi Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study
    Hakan Andersson
    Department of Oncology, University of Gothenburg, Gothenburg, Sweden
    J Nucl Med 50:1153-60. 2009
  8. doi Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging
    Alexander B Stillebroer
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Nucl Med 53:82-9. 2012
  9. ncbi Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas
    L F Porrata
    Leukemia 21:2554-6. 2007
  10. doi Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice
    Rafke Schoffelen
    Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Nucl Med 51:1780-7. 2010

Research Grants

  1. DEFINING TOXICITY AND BENEFIT FOR RADIOIMMUNOTHERAPY
    Margaret Tempero; Fiscal Year: 1993
  2. Targeted liposomal radiotherapy of malignant mesothelioma
    Jiang He; Fiscal Year: 2009
  3. Targeted liposomal radiotherapy of malignant mesothelioma
    Jiang He; Fiscal Year: 2010
  4. CORE--RADIOIMMUNOTHERAPY
    Andrew Raubitschek; Fiscal Year: 2000
  5. Radioimmunotherapy for Multiple Myeloma
    Damian J Green; Fiscal Year: 2010
  6. Bispecific Antibody Engineering for AML RIT
    Oliver Press; Fiscal Year: 2009
  7. Bispecific Antibody Engineering for AML RIT
    OLIVER W contact PRESS; Fiscal Year: 2010
  8. Foundations of Pretargeted Radioimmunotherapy
    KARL WITTRUP; Fiscal Year: 2009
  9. Foundations of Pretargeted Radioimmunotherapy
    KARL WITTRUP; Fiscal Year: 2005
  10. Foundations of Pretargeted Radioimmunotherapy
    KARL WITTRUP; Fiscal Year: 2006

Detail Information

Publications279 found, 100 shown here

  1. pmc Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer
    Scott T Tagawa
    Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA
    Cancer 116:1075-83. 2010
    ..Future studies will include approaches to optimize patient selection and incorporate novel strategies to improve the success of anti-PSMA radioimmunotherapy.
  2. doi Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma
    Pierre Yves Salaun
    Nuclear Oncology Department, Cancer Research Center, INSERM U892, Universite de Nantes, Nantes, France
    Cancer 116:1053-8. 2010
    Significant antitumor effects were previously observed with radioimmunotherapy (RIT) using an anti-carcinoembryonic antigen (CEA) monoclonal antibody (F6) labeled with iodine-131 in medullary thyroid cancer (MTC)-bearing nude mice...
  3. ncbi 131I-tositumomab therapy as initial treatment for follicular lymphoma
    Mark S Kaminski
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109 0936, USA
    N Engl J Med 352:441-9. 2005
    Advanced-stage follicular B-cell lymphoma is considered incurable. Anti-CD20 radioimmunotherapy is effective in patients who have had a relapse after chemotherapy or who have refractory follicular lymphoma, but it has not been tested in ..
  4. pmc Cancer radioimmunotherapy
    Robert M Sharkey
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Immunotherapy 3:349-70. 2011
    Targeting of radionuclides with antibodies, or radioimmunotherapy, has been an active field of research spanning nearly 50 years, evolving with advancing technologies in molecular biology and chemistry, and with many important preclinical ..
  5. ncbi Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft
    Françoise Kraeber-Bodéré
    INSERM UMR 892 Cancer Research Center, Universite de Nantes, Nantes, France
    J Nucl Med 51:624-31. 2010
    A significant antitumor effect was previously observed with radioimmunotherapy using anti-carcinoembryonic antigen (131)I-F6 monoclonal antibody in medullary thyroid cancer-bearing nude mice...
  6. doi Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice
    Birgit Pfost
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 50:1700-8. 2009
    ....
  7. ncbi Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study
    Hakan Andersson
    Department of Oncology, University of Gothenburg, Gothenburg, Sweden
    J Nucl Med 50:1153-60. 2009
    ..The aim was to determine the pharmacokinetics for assessing absorbed dose to normal tissues and investigating toxicity...
  8. doi Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging
    Alexander B Stillebroer
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Nucl Med 53:82-9. 2012
    This study aimed to estimate the radiation absorbed doses to normal tissues and tumor lesions during radioimmunotherapy with (177)Lu-cG250...
  9. ncbi Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas
    L F Porrata
    Leukemia 21:2554-6. 2007
  10. doi Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice
    Rafke Schoffelen
    Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Nucl Med 51:1780-7. 2010
    Pretargeted radioimmunotherapy (PRIT) with bispecific antibodies in combination with a radiolabeled peptide reduces the radiation dose to normal tissues, especially the bone marrow...
  11. doi High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma
    Franck Morschhauser
    Service des Maladies du Sang, Centre Hospitalier Regional, L Universitaire de Lille, France
    J Clin Oncol 28:3709-16. 2010
    Fractionated radioimmunotherapy targeting CD22 may substantially improve responses and outcome in non-Hodgkin's lymphoma (NHL).
  12. ncbi Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis
    Karin Knogler
    Center for Radiopharmaceutical Science, ETH PSI USZ, Paul Scherrer Institute, CH 5232 Villigen, Switzerland
    Clin Cancer Res 13:603-11. 2007
    ..We examined the tumor-targeting and therapeutic effects of (67)Cu-labeled single amino acid mutant forms of anti-L1 monoclonal antibody chCE7 in nude mice with orthotopically implanted SKOV3ip human ovarian carcinoma cells...
  13. ncbi Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group
    Torsten Liersch
    Department of General Surgery, University of Gottingen, Gottingen, Germany
    Ann Surg Oncol 14:2577-90. 2007
    We tested whether adjuvant radioimmunotherapy (RAIT) given after R0 resection of liver metastases (LM) of colorectal cancer is safe and can improve survival...
  14. pmc Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
    R O Dillman
    Medical and Scientific Director, Hoag Cancer Center, Newport Beach, CA 92658, USA
    Clin Exp Med 6:1-12. 2006
    ..Clinical trials suggest that anti- CD20 radioimmunotherapy is superior to total body irradiation in patients undergoing stem cell supported therapy for B-cell lymphoma,..
  15. doi Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
    Michael F Leahy
    Department of Hematology, The University of Western Australia, Fremantle Hospital, Fremantle, Australia
    Blood 117:45-52. 2011
    b>Radioimmunotherapy of indolent non-Hodgkin lymphoma (NHL) has achieved objective response rates in clinical trials comparable with standard rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, but is ..
  16. ncbi Radioimmunotherapy and colorectal cancer
    M J Koppe
    Department of Surgery, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Br J Surg 92:264-76. 2005
    Despite the success of radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (Mabs) directed against tumour-associated antigens in the treatment of non-Hodgkin's lymphoma, therapeutic success in solid tumours has been modest...
  17. ncbi Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
    M S Kaminski
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0936, USA
    Blood 96:1259-66. 2000
    CD20-targeted radioimmunotherapy is a promising new treatment for B-cell non-Hodgkin lymphoma (NHL)...
  18. ncbi Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship
    Nathan Lawrentschuk
    Department of Surgery, University of Melbourne, Australia
    BJU Int 97:916-22. 2006
  19. doi Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma
    B Esmaeli
    Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 20:709-14. 2009
    ..To determine the efficacy and side-effects of (90)Y ibritumomab tiuxetan (Zevalin) as front-line treatment in patients with early-stage extranodal indolent lymphoma of the ocular adnexa (orbit, conjunctiva, or eyelid)...
  20. ncbi The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab
    Richard L Wahl
    Division of Nuclear Medicine, Johns Hopkins Medical Institutions, Department of Radiology, Baltimore, MD 21287 0817, USA
    Semin Oncol 30:31-8. 2003
    b>Radioimmunotherapy (RIT) is a promising emerging therapy for non-Hodgkin's lymphoma and may ultimately prove useful in the treatment of other tumors...
  21. doi Clinical radioimmunotherapy--the role of radiobiology
    Jean Pierre Pouget
    Direction de la RadioProtection de l Homme, Institut de Radioprotection et de Surete Nucleaire, Fontenay aux Roses, F 92262, France
    Nat Rev Clin Oncol 8:720-34. 2011
    Conventional external-beam radiation therapy is dedicated to the treatment of localized disease, whereas radioimmunotherapy represents an innovative tool for the treatment of local or diffuse tumors...
  22. pmc PET/CT Imaging and Radioimmunotherapy of Prostate Cancer
    Kirsten Bouchelouche
    PET and Cyclotron Unit, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, Denmark
    Semin Nucl Med 41:29-44. 2011
    ..Prostate cancer represents an attractive target for radioimmunotherapy (RIT) for several reasons, including pattern of metastatic spread (lymph nodes and bone marrow, sites with ..
  23. ncbi Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy
    M G Steffens
    Department of Urology, University Hospital Nijmegen, The Netherlands
    Cancer Res 59:1615-9. 1999
    ..the intratumoral distribution of the antibody is highly heterogeneous, which may limit the efficacy of radioimmunotherapy. A number of highly dynamic physiological factors have been postulated that may contribute to heterogeneous ..
  24. doi Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide
    Eric Frampas
    Centre de Recherche en Cancérologie Nantes Angers, Universite de Nantes, INSERM, UMR 892, 8 quai Moncousu, BP 70721, 44007 Nantes Cedex 1, France
    Eur J Nucl Med Mol Imaging 38:2153-64. 2011
    We investigated influences of pretargeting variables, tumor location, and radionuclides in pretargeted radioimmunotherapy (PRIT) as well as estimated tumor absorbed doses.
  25. doi Adjuvant radioimmunotherapy improves survival of rats after resection of colorectal liver metastases
    Gabie M De Jong
    Division of Abdominal and Oncological Surgery, Department of Surgery, Radboud University Nijmegen Medical Centre, Geert Grooteplein zuid 10, Nijmegen, The Netherlands
    Ann Surg 253:336-41. 2011
    The aim of this study was to test the hypothesis that adjuvant radioimmunotherapy (RIT) prevents recurrent liver metastases and/or results in improved survival after tumorectomy in an experimental model.
  26. ncbi Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy
    Aurore Oudoux
    Nuclear Medicine, University Hospital, 44093 Nantes, France
    J Clin Endocrinol Metab 92:4590-7. 2007
    ..Patients with progressive medullary thyroid carcinoma (MTC) undergo multiple imaging procedures for diagnosis of relapse and staging...
  27. ncbi Pretargeted radioimmunotherapy of cancer: progress step by step
    Otto C Boerman
    Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
    J Nucl Med 44:400-11. 2003
    To enhance the therapeutic efficacy of radioimmunotherapy of cancer, several pretargeting strategies have been developed...
  28. pmc Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy
    Robert M Sharkey
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ, USA
    Semin Nucl Med 40:190-203. 2010
    ..However, for many other cancers, radioimmunotherapy has been ineffective, being limited by prolonged exposure to the highly radiosensitive bone marrow...
  29. pmc Radioimmunotherapy improves survival of rats with microscopic liver metastases of colorectal origin
    Gabie M De Jong
    Department of Surgery, Division of Abdominal and Oncological Surgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Ann Surg Oncol 16:2065-73. 2009
    ..The aim of the present study was to assess the efficacy of radioimmunotherapy (RIT) with a radiolabeled monoclonal antibody (mAb) to treat experimental colorectal liver metastases.
  30. ncbi High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model
    T M Behr
    Department of Nuclear Medicine, Georg August University, Gottingen, Germany
    Cancer Res 59:2635-43. 1999
    Recent studies suggest that radioimmunotherapy (RIT) with high-linear energy transfer (LET) radiation may have therapeutic advantages over conventional low-LET (e.g., beta-) emissions...
  31. ncbi Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer
    Jing Chen
    Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No 1095, Jiefang Dadao, 430030 Wuhan, People s Republic of China
    Cancer Lett 231:169-75. 2006
    ..The results suggests that the radioimmunotherapy of intratumoral injection of 131I-Sc-7269-DMN may be safe and efficient for the treatment of liver cancer...
  32. ncbi Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
    G A Wiseman
    Department of Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Eur J Nucl Med 27:766-77. 2000
    ..The only toxicity of note is hematologic and is not correlated to red marrow radiation absorbed dose estimates or T(1/2), reflecting that hematologic toxicity is dependent on bone marrow reserve in this heavily pretreated population...
  33. pmc A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
    Auayporn Nademanee
    Division of Hematology and Hemapoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    Blood 106:2896-902. 2005
    ..We conclude that high-dose 90Y-ibritumomab tiuxetan can be combined safely with high-dose etoposide and cyclophosphamide without an increase in transplant-related toxicity or delayed engraftment...
  34. doi Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
    Tim M Illidge
    School of Cancer and Imaging Sciences, University of Manchester, Manchester, UK
    Blood 113:1412-21. 2009
    ..of induction therapy with multiple doses of rituximab on the subsequent efficacy and toxicity of anti-CD20 radioimmunotherapy is unknown...
  35. ncbi 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital
    J Harvey Turner
    Department of Nuclear Medicine, Fremantle Hospital and Department of Medicine, The University of Western Australia, Fremantle, Western Australia, Australia
    Cancer Biother Radiopharm 18:513-24. 2003
    In order to increase the availability and affordability of radioimmunotherapy of refractory or relapsed non-Hodgkins lymphoma, we developed and evaluated radioiodinated rituximab in an ongoing physician-sponsored Phase II Clinical Trial...
  36. ncbi Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison
    Barry W Wessels
    Department of Radiation Oncology, Case Western Reserve University, Cleveland, Ohio
    J Nucl Med 45:1725-33. 2004
    ..In this work, we have analyzed reported marrow dosimetry results from radioimmunotherapy trials and recalculated marrow absorbed doses at a central facility using a standard blood model with ..
  37. ncbi Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients
    Stefanie Sauer
    Department of Pathology, Campus Benjamin Franklin, Charite Universitatsmedizin, Berlin, Germany
    Blood 113:2265-74. 2009
    ..In 2 relapsed Hodgkin lymphoma patients(131)I-L19SIP radioimmunotherapy induced a sustained partial response, qualifying ED-B FN as a promising target for antibody-based lymphoma ..
  38. ncbi Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity
    Jörgen Elgqvist
    Department of Radiation Physics, The Sahlgrenska Academy at Goteborg University, SE 413 45 Goteborg, Sweden
    Nucl Med Biol 33:1065-72. 2006
    The aim of this study was to investigate the therapeutic efficacy and myelotoxicity during fractionated radioimmunotherapy of ovarian cancer in mice...
  39. doi Radioimmunotherapy of lymphoma: Bexxar and Zevalin
    Stanley J Goldsmith
    Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Cornell College of Medicine, New York, NY 10065, USA
    Semin Nucl Med 40:122-35. 2010
    b>Radioimmunotherapy is a form of targeted radionuclide therapy that uses a monoclonal antibody to deliver localized radiation...
  40. ncbi A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas
    Tim Meyer
    UCL Cancer Institute, University College London, United Kingdom
    Clin Cancer Res 15:4484-92. 2009
    In preclinical models, radioimmunotherapy with (131)I-A5B7 anti-carcinoembryonic antigen (CEA) antibody ((131)I-A5B7) combined with the vascular disruptive agent combretastatin-A4-phosphate (CA4P) produced cures unlike either agent alone...
  41. ncbi Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma
    Ruby F Meredith
    Department of Radiation Oncology, University of Alabama Medical Center, Birmingham, AL, USA
    Int J Radiat Oncol Biol Phys 66:S15-22. 2006
    ..Two radioimmunotherapy agents that target the CD20 antigen, (131)I-tositumomab and (90)Y-ibritumomab tiuxetan, have been approved ..
  42. ncbi Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography
    Caroline Bodet-Milin
    Nuclear Medicine Department, University Hospital, Place Alexis Ricordeau, 44093 Nantes Cedex 1, France
    Haematologica 93:390-7. 2008
    The study aimed to evaluate FDG-PET imaging for early prediction of response to radioimmunotherapy in patients with non-Hodgkin's lymphoma.
  43. ncbi Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy
    Scott S Graves
    NeoRx Corporation, Seattle, Washington 98119 4114, USA
    Clin Cancer Res 9:3712-21. 2003
    Pretarget radioimmunotherapy (RIT) is a multistep strategy for cancer therapy designed to reduce nontarget organ exposure by uncoupling the tumor targeting moiety from the radioactive ligand...
  44. doi Perspectives of molecular imaging and radioimmunotherapy in lymphoma
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Room H 0101, Stanford, CA 94305 5427, USA
    Radiol Clin North Am 46:243-52, viii. 2008
    ..uses of 18F Fluoro-2-Deoxyglucose (18F FDG) PET and PET/CT for evaluation of lymphoma patients and use of radioimmunotherapy in lymphoma...
  45. doi Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model
    Sophie E Eriksson
    Department of Oncology, Lund University, Sweden
    Cancer Biother Radiopharm 27:134-40. 2012
    Fractionation is generally used as a mean to improve radioimmunotherapy (RIT)...
  46. doi Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement
    Pierre Yves Salaun
    Nuclear Medicine Department, University Hospital and ICO Gauducheau Cancer Institute, IRCNA, Cancer Research Center, Universite de Nantes, INSERM, UMR 892, Nantes, France
    J Nucl Med 53:1185-92. 2012
    ..This prospective phase II multicenter trial evaluated the efficacy and safety of anti-CEA pretargeted radioimmunotherapy (pRAIT) in rapidly progressing metastatic MTC patients and also how serum biomarker DTs correlate with ..
  47. ncbi Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model
    Emma Y Song
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Kogarah, UK
    Cancer Biol Ther 7:76-80. 2008
    ..The aim of this study was to investigate the effect of targeted alpha therapy (TAT) for the control of ascites in an OC ascites mouse model; the biodistribution of (213)Bi-C595 and its long term toxicity...
  48. ncbi Radioimmunotherapy with 131I-rituximab: what we know and what we don't know
    Malik E Juweid
    Cancer Biother Radiopharm 18:489-95. 2003
  49. doi Outpatient 131I-rituximab radioimmunotherapy for non-Hodgkin lymphoma: a study in safety
    Phillipe J Calais
    Department of Nuclear Medicine, The University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia
    Clin Nucl Med 37:732-7. 2012
    This study aimed to establish the safety of outpatient 131I-rituximab radioimmunotherapy by measuring the radiation exposure of hospital staff, carers, and members of the public and by estimating the environmental impact of radioactive ..
  50. ncbi Radioimmunotherapy: optimizing delivery to solid tumors
    Vineeth Rajkumar
    UCL Cancer Institute, University College London, 72 Huntley St, London WCIE 6BT, UK
    Ther Deliv 2:567-72. 2011
    b>Radioimmunotherapy (RIT) is a cancer treatment that exploits the specific targeting capability of monoclonal antibodies to deliver cytotoxic radionuclides to antigen-expressing tumor cells or stromal targets...
  51. ncbi (212)Pb@C(60) and its water-soluble derivatives: synthesis, stability, and suitability for radioimmunotherapy
    Michael D Diener
    TDA Research Incorporated, 12345 West 52nd Avenue, Wheat Ridge, Colorado 80033 and Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, Tennessee 37831 6229, USA
    J Am Chem Soc 129:5131-8. 2007
    Fullerenes could potentially play a valuable role in radioimmunotherapy by more stably encapsulating radionuclides, especially where conventional chelation chemistry is inadequate due to the physical and/or chemical properties of the ..
  52. ncbi Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience
    D R Colnot
    Department of Otolaryngology-Head and Neck Surgery, University Hospital Vrije Universiteit, De Boelelaan 1117, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Head Neck 23:559-65. 2001
    ..An effective adjuvant therapy is required for these patients. Among novel approaches is radioimmunotherapy, in which monoclonal antibodies (MAbs) are used for selective delivery of radiation to tumor cells...
  53. ncbi Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma
    Kevin J Hamblett
    Department of Bioengineering, Medicine, University of Washington, Seattle, Washington 98195, USA
    Bioconjug Chem 16:131-8. 2005
    One pretargeting approach to cancer radioimmunotherapy utilizes an antibody-streptavidin conjugate that is first localized to the tumor...
  54. pmc Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy
    Jeffrey N Bryan
    Department of Veterinary Medicine and Surgery, University of Missouri Columbia, USA
    Cancer Biol Ther 11:1001-7. 2011
    We previously described a two-antibody model of (64)Cu radioimmunotherapy to evaluate low-dose, solid-tumor response...
  55. ncbi Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma
    Jane N Winter
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Clin Lymphoma 5:S22-6. 2004
    Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing ..
  56. ncbi Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine
    Rhona Stein
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Cancer 94:51-61. 2002
    ..the efficacy of chemotherapy for medullary thyroid carcinoma (MTC), we evaluated the effect of combining radioimmunotherapy (RAIT) with 90Y-anticarcinoembryonic antigen (CEA) monoclonal antibody MN-14 and chemotherapy in nude mice ..
  57. doi Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report
    Thomas E Witzig
    Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 52:1188-99. 2011
    b>Radioimmunotherapy (RIT) with (90)Y-ibritumomab tiuxetan or (131)I-tositumomab combines a radiation-emitting radionuclide with an antibody targeting CD20 to treat B-cell non-Hodgkin lymphoma...
  58. ncbi Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry
    Cecilia Hindorf
    Department of Radiation Physics, Lund University, Lund, Sweden
    Cancer 94:1235-9. 2002
    The method for red marrow dosimetry in radioimmunotherapy, in the absence of specific activity uptake in red marrow, is based on the activity measured in the blood or plasma...
  59. ncbi Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients
    Cecilia Hindorf
    Department of Medical Radiation Physics, Jubileum Institute, Lund University, SE 221 85 Lund, Sweden
    Clin Cancer Res 9:4003S-6S. 2003
    ..The purpose of the present work is to demonstrate the limitations in current internal dosimetry protocols that assume a fixed tumor mass in lymphoma patients, using a fractionated radioimmunotherapy schedule and using a single infusion.
  60. doi Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma
    Thomas Cazaentre
    Service de Médecine Nucléaire et Imagerie Fonctionnelle, CHU Lille, 59000, Lille, France
    Eur J Nucl Med Mol Imaging 37:494-504. 2010
    b>Radioimmunotherapy (RIT) is a new treatment option for patients with non-Hodgkin lymphoma (NHL). Response to RIT currently remains difficult to predict using conventional prognostic factors and could be refined using functional imaging...
  61. pmc Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab
    Zhaofei Liu
    Medical Isotopes Research Center, Peking University, 38 Xueyuan Road, Beijing 100191, China
    Mol Cancer Ther 9:2297-308. 2010
    ..Here, we report for the first time the radioimmunotherapy (RIT) of EGFR-positive human head and neck cancer in a nude mouse model using pure beta(-) emitter (90)Y-..
  62. ncbi Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei
    Y Kvinnsland
    Department of Nuclear Medicine, The Norwegian Radium Hospital, 0310, Norway
    Radiat Res 155:288-96. 2001
    ..The magnitudes of the differences were found to be a function of the fractions of mean specific energy delivered by surrounding activity and by activity bound to the cells...
  63. ncbi Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia
    Russell Schilder
    Fox Chase Comprehensive Cancer Center, Philadelphia, PA 1911 2412, USA
    Cancer Biother Radiopharm 19:478-81. 2004
    ..Patients received a single course of ibritumomab tiuxetan radioimmunotherapy, with 90Y ibritumomab tiuxetan administered at 0.3 mCi/kg (compared to a standard dose of 0.4 mCi/kg)...
  64. ncbi High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study
    Thomas M Behr
    Department of Nuclear Medicine, Georg August University of Gottingen, Gottingen, Germany
    Cancer 94:1363-72. 2002
    ..been used successfully as a target molecule for conventional low-dose, as well as high-dose, myeloablative radioimmunotherapy (RIT) of B-cell non-Hodgkin lymphoma (NHL)...
  65. pmc Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 118:703-11. 2011
    Pretargeted radioimmunotherapy (PRIT) using an anti-CD45 antibody (Ab)-streptavidin (SA) conjugate and DOTA-biotin labeled with β-emitting radionuclides has been explored as a strategy to decrease relapse and toxicity...
  66. ncbi Pretargeted radioimmunotherapy for B-cell lymphomas
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 13:5598s-5603s. 2007
    ..We have investigated the potential utility of pretargeted radioimmunotherapy using monoclonal antibody-streptavidin, immunoconjugates, and fusion proteins in combination with N-..
  67. ncbi Doubly radiolabeled liposomes for pretargeted radioimmunotherapy
    M Mougin-Degraef
    Département de Recherche en Cancérologie, INSERM, U601, Universite de Nantes, 9 quai Moncousu 44093, Nantes Cedex 1, France
    Int J Pharm 344:110-7. 2007
    The aim of this study was to design liposomes as radioactivity carriers for pretargeted radioimmunotherapy with favorable pharmacokinetic parameters...
  68. ncbi A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies
    Yukang Lin
    The Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Cancer Res 66:3884-92. 2006
    ..We now show the superiority of pretargeted radioimmunotherapy (PRIT) compared with conventional radioimmunotherapy using a recombinant tetravalent single-chain Ab-..
  69. ncbi Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity
    Shankar Vallabhajosula
    Department of Radiology, Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York 10021, USA
    Clin Cancer Res 11:7195s-7200s. 2005
    Bone marrow is the dose-limiting organ in radioimmunotherapy. Fractionated dose regimens may decrease myelotoxicity and increase greater total administered dose...
  70. ncbi Editorial: what ails solid tumor radioimmunotherapy?
    Chaitanya Divgi
    Cancer Biother Radiopharm 21:81-4. 2006
  71. ncbi Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin
    Zhengsheng Yao
    Department of Nuclear Medicine, Warren G Magnuson Clinical Center, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:3137-46. 2004
    The use of an alpha emitter for radioimmunotherapy has potential advantages compared with beta emitters...
  72. ncbi Engineered single chain antibody fragments for radioimmunotherapy
    A Huhalov
    Cancer Research UK Imaging and Targeting Group, Department of Oncology, Royal Free and University College Medical School, Royal Free Campus London, United Kingdom
    Q J Nucl Med Mol Imaging 48:279-88. 2004
    An ideal molecule to deliver radioimmunotherapy (RIT) would be target specific and have prolonged residence time at high concentrations in the tumour with rapid clearance from normal tissues. It would also be non-immunogenic...
  73. ncbi Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection
    Ekaterina Dadachova
    Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Infect Dis 193:1427-36. 2006
    The usefulness of radioimmunotherapy (RIT) for infectious diseases was recently demonstrated for several fungal and bacterial infections, but the mechanisms by which RIT is effective against microbes are uncertain.
  74. ncbi High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
    Carol M Richman
    University of California Davis, Sacramento, California 95817, USA
    Clin Cancer Res 11:5920-7. 2005
    Although radioimmunotherapy alone is effective in lymphoma, its application to solid tumors will likely require a combined modality approach...
  75. ncbi Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes
    Ekaterina Dadachova
    Department of Nuclear Medicine, Albert Einstein College of Medicine, 1695A Eastchester Road, Bronx, NY 10461, USA
    J Nucl Med 45:313-20. 2004
    ..One novel strategy is to use radioimmunotherapy (RIT) with fungal-binding monoclonal antibodies (mAbs) labeled with radionuclides...
  76. pmc Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models
    E Dadachova
    Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Antimicrob Agents Chemother 48:1004-6. 2004
    We evaluated acute hematological and long-term pulmonary toxicity of radioimmunotherapy in murine models of Cryptococcus neoformans infection...
  77. pmc Feasibility of radioimmunotherapy of experimental pneumococcal infection
    E Dadachova
    Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Antimicrob Agents Chemother 48:1624-9. 2004
    ..We have recently established that radioimmunotherapy (RIT) can be used to treat experimental fungal infections in mice...
  78. ncbi Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials
    Zhi Nan Chen
    Cell Engineering Research Centre and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi an, China
    Int J Radiat Oncol Biol Phys 65:435-44. 2006
    ..We developed iodine (131I) metuximab injection (Licartin), a novel 131I-labeled HAb18G/CD147-specific monoclonal antibody Fab'2 fragment, and evaluated its safety, pharmacokinetics, and clinical efficacy on HCC in Phase I/II trials...
  79. ncbi Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy
    Jason L J Dearling
    Cancer Research UK Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School, University College London, London, UK
    Clin Cancer Res 13:1903-10. 2007
    The efficacy of solid tumor radioimmunotherapy is reduced by heterogeneous tumor distribution of the radionuclide, with dose mainly deposited in the normoxic region and by the relative radioresistance of hypoxic tumor cells...
  80. ncbi The radiation biology of radioimmunotherapy
    K L Dixon
    Department of Physics, The University of British Colombia, Canada
    Nucl Med Commun 24:951-7. 2003
    The treatment of cancer is a wide and varied field, encompassing many methods and modalities. Radioimmunotherapy is a technique which utilizes the ablative properties of radiation by delivering radioactive particles directly to the tumour ..
  81. ncbi Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer
    R T O'Donnell
    Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis Medical Center, Sacramento, California 95816
    Clin Cancer Res 7:1561-8. 2001
    ..b>Radioimmunotherapy (RIT) uses a tumor-specific monoclonal antibody to deliver systemic, targeted radiation to cancer...
  82. pmc Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection
    Ruth A Bryan
    Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Infect Dis 202:633-7. 2010
    b>Radioimmunotherapy (RIT) prolongs the survival of mice infected with Cryptococcus neoformans. To compare the efficacy of RIT with that of amphotericin B, we infected AJ/Cr mice intravenously with either nonmelanized or melanized C...
  83. doi Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme
    Anand Veeravagu
    Molecular Imaging Program at Stanford, Department of Radiology and Bio X Program, Stanford University School of Medicine, Stanford, California 94305 5484, USA
    Clin Cancer Res 14:7330-9. 2008
    ..The purpose of this study was to evaluate the efficacy of a novel 90Y-Abegrin radioimmunotherapeutic agent in murine xenograft glioblastoma models with noninvasive in vivo molecular imaging modalities...
  84. ncbi Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6
    ROBERT T O'DONNELL
    Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California Davis Medical Center, Sacramento, California 95816, USA
    Prostate 50:27-37. 2002
    ..55 MBq;150 microCi) has resulted in durable responses. To make radioimmunotherapy (RIT) more effective, the radiation-enhancing drugs Taxol (paclitaxel) and Taxotere (docetaxel) were tested ..
  85. pmc Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells
    Ruth A Bryan
    Departments of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Antimicrob Agents Chemother 53:1679-82. 2009
    We investigated the utility of radioimmunotherapy (RIT) in the treatment of experimental cryptococcal infection with high-inoculum and the possibility of RIT treatment selecting for fungal cells with radiation-resistant phenotypes...
  86. ncbi Model prediction of treatment planning for dose-fractionated radioimmunotherapy
    Sui Shen
    Department of Radiation Oncology, University of Alabama at Birmingham, 35294, USA
    Cancer 94:1264-9. 2002
    Clinical trials of radioimmunotherapy (RIT) often use dose fractionation to reduce marrow toxicity. The dosing scheme can be optimized if marrow and tumor cell kinetics following radiation exposure are known.
  87. ncbi Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma
    Zhao Chong Zeng
    Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, P R China
    Eur J Nucl Med Mol Imaging 29:1657-68. 2002
    It has previously been observed in animal studies that, at equivalent doses, radioimmunotherapy (RIT) is 2.5 times more effective than multiple fractions of external beam radiation therapy (EBRT) in inhibiting tumour growth...
  88. ncbi FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study
    E Lopci
    Nuclear Medicine Department, University Hospital S Orsola Malpighi, Bologna, Italy
    Ann Oncol 21:1877-83. 2010
    ..of this study is the 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) evaluation following radioimmunotherapy (RIT) with ibritumomab tiuxetan Y 90 in patients with non-Hodgkin's follicular lymphoma (FL).
  89. ncbi Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle 98109, USA
    Blood 101:2340-8. 2003
    ..These lymphoma xenograft data suggest that pretargeted radioimmunotherapy using either anti-CD20 or anti-CD45 conjugates is highly effective and minimally toxic.
  90. pmc Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors
    Fares Al-Ejeh
    Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, South Australia, Australia
    PLoS ONE 4:e4630. 2009
    ..inefficient delivery of therapeutic doses of radionuclides to solid tumors limits the clinical utility of radioimmunotherapy. We aim to test the therapeutic utility of Yttrium-90 ((90)Y)-radio-conjugates of a monoclonal antibody, ..
  91. ncbi Rationales, evidence, and design considerations for fractionated radioimmunotherapy
    Gerald L DeNardo
    Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California, Davis Medical Center, Sacramento, California 95816, USA
    Cancer 94:1332-48. 2002
    ..used in the broader context of administration of multiple, rather than single, doses of radionuclide for radioimmunotherapy (RIT) or other targeted radionuclide therapies...
  92. ncbi A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases
    Yonggang Lv
    Department of Biomedical Engineering, The City College of New York, New York, New York 10031, USA
    J Nucl Med 50:1324-31. 2009
    b>Radioimmunotherapy can effectively treat leptomeningeal metastases when radiolabeled antibodies are administered into the cerebrospinal fluid (CSF)...
  93. ncbi Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer
    A Murray
    Department of Medical Physics, Medical School, Queen's Medical Centre, Nottingham, United Kingdom
    J Nucl Med 42:726-32. 2001
    ..MUC1 mucin is overexpressed on bladder tumors and represents a useful target for radioimmunoscintigraphy and radioimmunotherapy. We report on the production and initial tracer studies of a 188Re-antibody complex directed against this ..
  94. pmc Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6
    Rébécca Phaeton
    Department of Obstetrics and Gynecology and Women s Health, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY, USA
    Cancer Biol Ther 10:1041-7. 2010
    ..b>Radioimmunotherapy employs systemically administered radiolabeled monoclonal antibodies (mAbs) that bind to tumor-associated ..
  95. pmc Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma
    Peter L Roberson
    Department of Radiation Oncology, University of Michigan, 519 W William St, Argus I, Ann Arbor, MI 48103 4943, USA
    Eur J Nucl Med Mol Imaging 38:874-83. 2011
    ..Treatment with tositumomab and (131)I-tositumomab anti-CD20 radioimmunotherapy (BEXXAR) yields a cold antibody antitumor response (cold protein effect) and a radiation response...
  96. ncbi Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells
    Claudia Friesen
    University Children s Hospital, Prittwitzstrasse 43, 89075 Ulm, Germany
    Eur J Nucl Med Mol Imaging 30:1251-61. 2003
    Beta-irradiation used for systemic radioimmunotherapy (RIT) is a promising treatment approach for high-risk leukaemia and lymphoma...
  97. pmc Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT
    Alexandra D Jensen
    Dept of Radiation, Oncology INF, Heidelberg Germany
    BMC Cancer 11:182. 2011
    ..Combined radioimmunotherapy with cetuximab as well as modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) and ..
  98. doi Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop
    Pier Luigi Zinzani
    Institute of Hematology and Oncology Seragnoli, Via Massarenti 9, 40138 Bologna, Italy
    Eur J Cancer 44:366-73. 2008
    ..This approach would maximise the therapeutic potential of this agent by encouraging its use early in the disease course of follicular lymphomas...
  99. pmc The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice
    Rébécca Phaeton
    Department of Obstetrics and Gynecology and Women s Health, Division of Gynecologic Oncology, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY 10461, USA
    Cancer 116:1067-74. 2010
    ..The authors of this report recently demonstrated the efficacy of radioimmunotherapy (RIT) targeting viral oncoprotein E6 in the treatment of experimental cervical cancer...
  100. ncbi Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas
    W Debinski
    Department of Surgery, Pennsylvania State University, College of Medicine, Hershey 17033 0850, USA
    Clin Cancer Res 5:3143s-3147s. 1999
    ....
  101. ncbi Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8
    K Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 35:716-8. 2000
    ..Intrathecal antibody-based targeted therapies may have clinical potential for patients with leptomeningeal (LM) cancer...

Research Grants83

  1. DEFINING TOXICITY AND BENEFIT FOR RADIOIMMUNOTHERAPY
    Margaret Tempero; Fiscal Year: 1993
    ..Dr. Peter Leichner will be the Program Leader for the Laboratory Program for Dosimetry. He will perform all the dosimetry estimates with the assistance of Dr. Dalrymple who will participate in nuclear scan interpretations...
  2. Targeted liposomal radiotherapy of malignant mesothelioma
    Jiang He; Fiscal Year: 2009
    ..Highly selective tumor location and targeting are needed. Our long term goal is to develop effective radioimmunotherapy (RIT) for human cancers by marrying radiotherapy with nanotechnology...
  3. Targeted liposomal radiotherapy of malignant mesothelioma
    Jiang He; Fiscal Year: 2010
    ..Highly selective tumor location and targeting are needed. Our long term goal is to develop effective radioimmunotherapy (RIT) for human cancers by marrying radiotherapy with nanotechnology...
  4. CORE--RADIOIMMUNOTHERAPY
    Andrew Raubitschek; Fiscal Year: 2000
    Core E Radioimmunotherapy is designed to support Project I-Allogeneic Bone Marrow Transplantation for Hematologic Malignancy and Project II-Autologous Bone Marrow Transplantation for Hematologic Malignancy by providing the necessary ..
  5. Radioimmunotherapy for Multiple Myeloma
    Damian J Green; Fiscal Year: 2010
    ..There is a scientifically compelling rationale for high dose radioimmunotherapy (RIT) conditioning followed by stem cell rescue for MM...
  6. Bispecific Antibody Engineering for AML RIT
    Oliver Press; Fiscal Year: 2009
    ..of this research proposal is to maximize the cure rate of AML using a novel approach employing pretargeted radioimmunotherapy (PRIT) with genetically engineered bispecific antibodies...
  7. Bispecific Antibody Engineering for AML RIT
    OLIVER W contact PRESS; Fiscal Year: 2010
    ..of this research proposal is to maximize the cure rate of AML using a novel approach employing pretargeted radioimmunotherapy (PRIT) with genetically engineered bispecific antibodies...
  8. Foundations of Pretargeted Radioimmunotherapy
    KARL WITTRUP; Fiscal Year: 2009
    ..Delivery of cell-killing doses of ionizing radiation to tumors is the objective of antibody-directed radioimmunotherapy (RIT)...
  9. Foundations of Pretargeted Radioimmunotherapy
    KARL WITTRUP; Fiscal Year: 2005
    Delivery of cell-killing doses of ionizing radiation to tumors is the objective of antibody-directed radioimmunotherapy (RIT)...
  10. Foundations of Pretargeted Radioimmunotherapy
    KARL WITTRUP; Fiscal Year: 2006
    ..Delivery of cell-killing doses of ionizing radiation to tumors is the objective of antibody-directed radioimmunotherapy (RIT)...
  11. NOVEL APPROACHES TO RADIO-IMMUNOCONJUGATE DOSIMETRY
    Lee Chin; Fiscal Year: 1990
    Most currently existing methods used to determine doses during radioimmunotherapy (RIT) often rely on the false assumption of a spatially homogeneous radio-innumoconjugate (RIC) distribution throughout the tumor...
  12. Foundations of Pretargeted Radioimmunotherapy
    KARL WITTRUP; Fiscal Year: 2007
    ..Delivery of cell-killing doses of ionizing radiation to tumors is the objective of antibody-directed radioimmunotherapy (RIT)...
  13. Combinatorial Peptide Libraries for Biodegradable Linkers to Decrease Normal Tiss
    Kit Lam; Fiscal Year: 2004
    The goal of this project is to develop highly effective cancer-targeting agents for cancer therapy. Radioimmunotherapy (RIT) has proven to be useful in cancer patients...
  14. CD45 Pretargeted Radioimmunotherapy for AML
    Oliver Press; Fiscal Year: 2009
    ..The objective of this research proposal is to improve the cure rate of AML using radioimmunotherapy (RIT) targeting the CD45 cell antigen...
  15. CD45 Pretargeted Radioimmunotherapy for AML
    Oliver W Press; Fiscal Year: 2010
    ..The objective of this research proposal is to improve the cure rate of AML using radioimmunotherapy (RIT) targeting the CD45 cell antigen...
  16. CANCER IMMUNOTHERAPEUTICS PROGRAM
    Andrew Raubitschek; Fiscal Year: 2003
    ..The program is an outgrowth of two major research efforts at COH, Radioimmunotherapy and Hematopoietic Transplantation for Hematologic Malignancies...
  17. RADIOIMMUNOTHERAPY AND BONE MARROW TRANSPLANTATION IN HEMATOLOGIC MALIGNANCY
    Andrew Raubitschek; Fiscal Year: 1999
    ..Further modification of this DOTA chelate will be evaluated as potential reagents for clinical utility in the treatment of the leukemias and lymphomas covered under this study. ..
  18. NEW BCAS FOR RADIOIMMUNOTHERAPY WITH RADIOMETALS
    Donald Buchsbaum; Fiscal Year: 2000
    ..The experiments described in this application will provide answers to these questions. These studies would establish the rationale for human clinical RIT trials in patients with Jp. cancer using HuCC49ACH2. ..
  19. NEW BCAS FOR RADIOIMMUNOTHERAPY WITH RADIOMETALS
    Donald Buchsbaum; Fiscal Year: 1999
    ..The experiments described in this application will provide answers to these questions. These studies would establish the rationale for human clinical RIT trials in patients with Jp. cancer using HuCC49ACH2. ..
  20. NEW BCAS FOR RADIOIMMUNOTHERAPY WITH RADIOMETALS
    Donald Buchsbaum; Fiscal Year: 2001
    ..The experiments described in this application will provide answers to these questions. These studies would establish the rationale for human clinical RIT trials in patients with Jp. cancer using HuCC49ACH2. ..
  21. THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES
    Oliver Press; Fiscal Year: 2005
    ..In Dr. Press' Project, we will investigate the potential of pretargeted radioimmunotherapy (RIT) with tetravalent anti-CD20 and anti- CD45 (scFv)4-streptavidin (SA) fusion proteins and radiobiotin ..
  22. THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES
    Oliver Press; Fiscal Year: 2007
    ..In Dr. Press' Project, we will investigate the potential of pretargeted radioimmunotherapy (RIT) with tetravalent anti-CD20 and anti- CD45 (scFv)4-streptavidin (SA) fusion proteins and radiobiotin ..
  23. THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES
    Oliver Press; Fiscal Year: 2006
    ..In Dr. Press' Project, we will investigate the potential of pretargeted radioimmunotherapy (RIT) with tetravalent anti-CD20 and anti- CD45 (scFv)4-streptavidin (SA) fusion proteins and radiobiotin ..
  24. THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES
    Oliver Press; Fiscal Year: 2009
    ..In Dr. Press' Project, we will investigate the potential of pretargeted radioimmunotherapy (RIT) with tetravalent anti-CD20 and anti- CD45 (scFv)4-streptavidin (SA) fusion proteins and radiobiotin ..
  25. THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES
    Oliver W Press; Fiscal Year: 2010
    ..In Dr. Press' Project, we will investigate the potential of pretargeted radioimmunotherapy (RIT) with tetravalent anti-CD20 and anti- CD45 (scFv)4-streptavidin (SA) fusion proteins and radiobiotin ..
  26. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2002
    ..treatment approach for MM and WM patients involves use of antibody mediated immunotherapy (serotherapy) and radioimmunotherapy. As part of our efforts to develop serotherapy for PCD, we have sought to target tumor selective antigens on ..
  27. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2003
    ..treatment approach for MM and WM patients involves use of antibody mediated immunotherapy (serotherapy) and radioimmunotherapy. As part of our efforts to develop serotherapy for PCD, we have sought to target tumor selective antigens on ..
  28. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2004
    ..treatment approach for MM and WM patients involves use of antibody mediated immunotherapy (serotherapy) and radioimmunotherapy. As part of our efforts to develop serotherapy for PCD, we have sought to target tumor selective antigens on ..
  29. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2001
    ..treatment approach for MM and WM patients involves use of antibody mediated immunotherapy (serotherapy) and radioimmunotherapy. As part of our efforts to develop serotherapy for PCD, we have sought to target tumor selective antigens on ..
  30. Anti-CD30 Radioimmunotherapy of Lymphoma
    Andrew Raubitschek; Fiscal Year: 2004
    ..b>Radioimmunotherapy offers an attractive therapeutic option, administering targeted radiation to sites of disease...
  31. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen Forman; Fiscal Year: 2007
    ..This grant consists of four translational clinical projects and three cores. Project I entitled "Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia" is focused on ..
  32. Hematopoietic Cell Transplantation for Malignancies
    Stephen Forman; Fiscal Year: 2006
    ..This grant consists of four translational clinical projects and three cores. Project I entitled "Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia" is focused on ..
  33. Hematopoietic Cell Transplantation for Hematologic Malignancies
    STEPHEN FORMA; Fiscal Year: 2007
    ..This grant consists of four translational clinical projects and three cores. Project I entitled "Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia" is focused on ..
  34. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen Forman; Fiscal Year: 2009
    ..This grant consists of four translational clinical projects and three cores. Project I entitled "Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia" is focused on ..
  35. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen J Forman; Fiscal Year: 2010
    ..This grant consists of four translational clinical projects and three cores. Project I entitled "Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia" is focused on ..
  36. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen J Forman; Fiscal Year: 2010
    ..This grant consists of four translational clinical projects and three cores. Project I entitled "Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia" is focused on ..
  37. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen Forman; Fiscal Year: 2009
    ..This grant consists of four translational clinical projects and three cores. Project I entitled "Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia" is focused on ..
  38. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen Forman; Fiscal Year: 2009
    ..This grant consists of four translational clinical projects and three cores. Project I entitled "Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia" is focused on ..
  39. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen J Forman; Fiscal Year: 2010
    ..This grant consists of four translational clinical projects and three cores. Project I entitled "Radioimmunotherapy-based Transplant Regimens for Treatment of B-cell Lymphoma and Acute Myelogenous Leukemia" is focused on ..
  40. Radioimmunotherapy for Lymphoma
    Thomas Witzig; Fiscal Year: 2001
    ..We anticipate that this novel radioimmunotherapy approach will result in more effective treatment for pts with NHL.
  41. Radioimmunotherapy for Lymphoma
    Thomas Witzig; Fiscal Year: 2002
    ..We anticipate that this novel radioimmunotherapy approach will result in more effective treatment for pts with NHL.
  42. PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver Press; Fiscal Year: 2009
    ..The objective of this research proposal is to optimize radioimmunotherapy (RIT) of B cell lymphomas utilizing pretargeting amplification strategies to improve the efficacy and ..
  43. PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver W Press; Fiscal Year: 2010
    ..The objective of this research proposal is to optimize radioimmunotherapy (RIT) of B cell lymphomas utilizing pretargeting amplification strategies to improve the efficacy and ..
  44. Combined radio- and immunotherapy of aggressive NHL
    WILLIAM WEGENER; Fiscal Year: 2009
    ..SBIR application is to translate rapidly preclinical findings that show the advantage of using a combination radioimmunotherapy plus immunotherapy treatment regimen that uses non-competing antibodies for the improved treatment of ..
  45. IMPROVED SECOND ANTIBODY RADIOIMMUNOTHERAPY OF CANCER
    ROBERT SHARKEY; Fiscal Year: 1999
    ..Investigator's Abstract): The long-term goals of this project is to evaluate procedures that will improve radioimmunotherapy (RAIT) by either increasing tumor accretion or decreasing normal tissue uptake, i.e...
  46. IMPROVED SECOND ANTIBODY RADIOIMMUNOTHERAPY OF CANCER
    ROBERT SHARKEY; Fiscal Year: 2000
    ..Investigator's Abstract): The long-term goals of this project is to evaluate procedures that will improve radioimmunotherapy (RAIT) by either increasing tumor accretion or decreasing normal tissue uptake, i.e...
  47. BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
    Claude Meares; Fiscal Year: 1999
    ..Antibodies have been conjugated to metal chelates for radioimmunotherapy and studied extensively in recent years, and are in clinical trials at various stages...
  48. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward A Neuwelt; Fiscal Year: 2010
    ..In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted...
  49. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2009
    ..In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted...
  50. TWO COMPARTMENT MODELS TO IMPROVE BRAIN TUMOR THERAPY
    Edward Neuwelt; Fiscal Year: 2009
    ..In aim 4 clinical trials of immunotherapy, radioimmunotherapy, and neurotoxicity in PCNSL will be conducted...
  51. RADIOIMMUNOTHERAPY--ISOTOPE AND ANTIBODY CHOICE
    Virginia Langmuir; Fiscal Year: 1990
    ..Because of the poor results with systemic chemotherapy, it is essential to find other forms of therapy. Radioimmunotherapy (RIT) is an active field of research...
  52. Radioimmunotherapy of opportunistic infections
    Ekaterina Dadachova; Fiscal Year: 2002
    ..This application proposes to develop radioimmunotherapy as an anti-infective strategy...
  53. Radioimmunotherapy of Acute Leukemia
    Eneida Nemecek; Fiscal Year: 2003
    ....
  54. Radioimmunotherapy of Acute Leukemia
    Eneida Nemecek; Fiscal Year: 2004
    ....
  55. Radioimmunotherapy of Acute Leukemia
    Eneida Nemecek; Fiscal Year: 2005
    ....
  56. Radioimmunotherapy of Acute Leukemia
    Eneida Nemecek; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  57. Radioimmunotherapy of Acute Leukemia
    Eneida Nemecek; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  58. Radioimmunotherapy of Acute Leukemia
    Eneida Nemecek; Fiscal Year: 2005
    ....
  59. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2000
    ..treatment approach for MM and WM patients involves use of antibody mediated immunotherapy (serotherapy) and radioimmunotherapy. As part of our efforts to develop serotherapy for PCD, we have sought to target tumor selective antigens on ..
  60. Fractionated, Dual-targeted radioimmunotherapy for follicular lymphoma
    Rebecca L Elstrom; Fiscal Year: 2010
    ..Recently, interest has grown in development of non-chemotherapy approaches to FL treatment. Radioimmunotherapy (RIT) involves the conjugation of a radionuclide with a monoclonal antibody, allowing delivery of radiation ..
  61. PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver Press; Fiscal Year: 2000
    ..pretargeting amplification strategies to improve the efficacy and decrease the toxicity of conventional radioimmunotherapy (RAIT)...
  62. COMBINED RADIOIMMUNOTHERAPY & CHEMOTHERAPY--COLON CANCER
    Malik Juweid; Fiscal Year: 1999
    ..The concept of combining adjuvant chemotherapy with FU-LV and radioimmunotherapy (RAIT) in colon cancer is especially attractive because of the additive and potentially synergistic anti-..
  63. Foundations of Pretargeted Radioimmunotherapy
    KARL D WITTRUP; Fiscal Year: 2010
    ..Delivery of cell-killing doses of ionizing radiation to tumors is the objective of antibody-directed radioimmunotherapy (RIT)...
  64. PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver Press; Fiscal Year: 1999
    ..pretargeting amplification strategies to improve the efficacy and decrease the toxicity of conventional radioimmunotherapy (RAIT)...
  65. Novel glutamate conjugates for radiotargeting PSMA
    John Babich; Fiscal Year: 2004
    The development of novel approaches for radioimmunoimaging and radioimmunotherapy is driven by the high incidence and mortality rate associated with prostate cancer in the United States...
  66. AUTOGRAFTING FOR LYMPHOMA
    Sandra Horning; Fiscal Year: 2002
    ..b>Radioimmunotherapy (RIT) with ibritumomab tiuxetan will be paired in a unique tandem in Phase I/II studies designed to test the ..
  67. PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver Press; Fiscal Year: 2001
    ..pretargeting amplification strategies to improve the efficacy and decrease the toxicity of conventional radioimmunotherapy (RAIT)...
  68. RADIOIMMUNOTHERAPY OF B CELL LYMPHOMA WITH ANTI CD74
    M Mattes; Fiscal Year: 2000
    DESCRIPTION: (Adapted from applicant's abstract) Recent results of cancer radioimmunotherapy (using radiolabeled antibodies) have been encouraging, especially for B-cell lymphoma...
  69. RADIOIMMUNOTHERAPY OF B CELL LYMPHOMA WITH ANTI CD74
    M Mattes; Fiscal Year: 2001
    DESCRIPTION: (Adapted from applicant's abstract) Recent results of cancer radioimmunotherapy (using radiolabeled antibodies) have been encouraging, especially for B-cell lymphoma...
  70. Improved Tumor Radiotherapy by MORF pretargeting
    Donald Hnatowich; Fiscal Year: 2002
    Despite several decades of effort, conventional radioimmunotherapy of hematopoietic and especially solid tumors is still providing marginal results. As such, alternative methods of treating these diseases are needed...
  71. Improved Tumor Radiotherapy by MORF pretargeting
    Donald Hnatowich; Fiscal Year: 2003
    Despite several decades of effort, conventional radioimmunotherapy of hematopoietic and especially solid tumors is still providing marginal results. As such, alternative methods of treating these diseases are needed...
  72. Improved Tumor Radiotherapy by MORF pretargeting
    Donald Hnatowich; Fiscal Year: 2004
    Despite several decades of effort, conventional radioimmunotherapy of hematopoietic and especially solid tumors is still providing marginal results. As such, alternative methods of treating these diseases are needed...
  73. Improved Tumor Radiotherapy by MORF pretargeting
    Donald Hnatowich; Fiscal Year: 2005
    Despite several decades of effort, conventional radioimmunotherapy of hematopoietic and especially solid tumors is still providing marginal results. As such, alternative methods of treating these diseases are needed...
  74. ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES
    Michael Zalutsky; Fiscal Year: 2007
    ..Iodine-131 is the most frequently used radionuclide in clinical radioimmunotherapy, but its usefulness has been compromised by in vivo dehalogenation of mAbs labeled via conventional methods...
  75. ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES
    Michael Zalutsky; Fiscal Year: 2001
    ..Iodine-131 is the most frequently used nuclide clinical radioimmunotherapy, but its usefulness has been compromised by in vivo dehalogenation of mAbs labeled via conventional ..
  76. NOVEL COMBINATION THERAPY OF NEUROBLASTOMA
    Nai Kong Cheung; Fiscal Year: 1999
    ..principles: (1) dose-intensive induction to improve remission rate and primary tumor control, (2) targeted radioimmunotherapy to eliminate occult metastatic disease, and (3) adjuvant monoclonal antibody for minimal residual disease...
  77. NOVEL COMBINATION THERAPY OF NEUROBLASTOMA
    Nai Kong Cheung; Fiscal Year: 2000
    ..principles: (1) dose-intensive induction to improve remission rate and primary tumor control, (2) targeted radioimmunotherapy to eliminate occult metastatic disease, and (3) adjuvant monoclonal antibody for minimal residual disease...